IN8BIO INC

For the period ended Dec 31, 2024. Filed Mar 13, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 13, 2025

INAB$0.94+1.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Changes in Stockholders’ Equity

(In thousands, except share data)

Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Deficit	Equity
Balance at December 31, 2022	24,545,157	$3	$83,941	$(61,212)	$22,732
Issuance of common stock, net of issuance costs	7,492,580	—	14,380	—	14,380
Issuance of private placement common stock, net of issuance costs	11,249,588	1	10,183	—	10,184
Issuance of private placement warrants, net of issuance costs	—	—	3,278	—	3,278
Stock-based compensation expense	—	—	4,370	—	4,370
Net loss	—	—	—	(30,007)	(30,007)
Balance at December 31, 2023	43,287,325	4	116,152	(91,219)	24,937
Issuance of common stock, net of issuance costs	3,479,623	—	3,816	—	3,816
Issuance of common stock upon exercise of Series A warrants, net of issuance costs	20,000	—	25	—	25
Issuance of private placement common stock, net of issuance costs	25,696,305	3	6,124	—	6,127
Issuance of private placement warrants, net of issuance costs	—	—	5,099	—	5,099
Issuance costs related to the December 2023 issuance of common stock	—	—	(89)	—	(89)
Stock-based compensation expense	—	—	5,000	—	5,000
Net loss	—	—	—	(30,437)	(30,437)
Balance at December 31, 2024	72,483,253	$7	$136,127	$(121,656)	$14,478

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.